RUNX1 and nonpapillary renal cell carcinoma: Taken together, we observed the LCOR-RUNX1-PLCL1 cascade accounts for multiple anti-tumor activities in ccRCC cells, upholding its candidacy as a novel diagnostic and therapeutic target.